Supernus to review Phase 2a data for SPN-820 in major depressive disorder on Oct 17

SUPERNUS PHARMACEUTICALS, INC.

Company will host webcast and conference call on October 17, 2024 at 4:30 PM ET.
Event will review data from open-label Phase 2a study of SPN-820 for major depressive disorder.
No specific results are disclosed in this filing; data will be presented during the webcast.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.